Friday, February 03, 2017 10:41:43 AM
It's easy to get emotional
and lose objectivity when management does things like this. Trust me, I get that. But I've found, more often than not, that selling into that impulse is the wrong thing to do. That's particularly true when the fundamentals seem so good and the balance sheet is improving.
Unfortunately, the upside gets curtailed with each successive offering unless they can significantly expand their markets either geographically or through product line expansion.
As the Oracle of Omaha said, the stock market is a mechanism for transferring money from the impatient to the patient (or something to that effect). Of course, WB wouldn't invest in a company like this, but such is my predicament.
and lose objectivity when management does things like this. Trust me, I get that. But I've found, more often than not, that selling into that impulse is the wrong thing to do. That's particularly true when the fundamentals seem so good and the balance sheet is improving.
Unfortunately, the upside gets curtailed with each successive offering unless they can significantly expand their markets either geographically or through product line expansion.
As the Oracle of Omaha said, the stock market is a mechanism for transferring money from the impatient to the patient (or something to that effect). Of course, WB wouldn't invest in a company like this, but such is my predicament.
Recent IDXG News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 08:15:35 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:38:48 PM
- Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results • GlobeNewswire Inc. • 03/30/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 09:05:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 11:46:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 02:05:32 PM
- Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure • GlobeNewswire Inc. • 01/20/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/03/2025 09:05:28 PM
- Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners • GlobeNewswire Inc. • 12/03/2025 05:12:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 09:45:44 PM
- Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results • GlobeNewswire Inc. • 11/12/2025 09:01:00 PM
- Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting • GlobeNewswire Inc. • 09/15/2025 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:28:44 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2025 08:30:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2025 08:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2025 08:25:28 PM
